HUTCHMED (00013.HK): Licenses global rights to KRAS-EGFR antibody-targeted conjugate HMPL-A830 to GSK for up to USD 1.295 billion

NewTimeSpace News: On 3 September 2026, HUTCHMED (China) Limited (stock code: 00013) announced that its subsidiary Hutchison MediPharma (Shanghai) Limited has entered into an exclusive development and licence agreement with a subsidiary of GSK plc, granting such GSK subsidiary rights to develop and commercialise HMPL-A830 worldwide, excluding Mainland China, Hong Kong, Macau and Taiwan, with clinical development initially focusing on colorectal cancer, pancreatic cancer and lung cancer indications. The agreement includes an upfront payment of USD 110 million, as well as potential development, regulatory and commercial milestone payments totalling up to USD 1.295 billion, plus royalties based on net sales.

HMPL-A830 is a first-in-class antibody-targeted conjugate (ATTC) candidate drug, comprising a highly selective and potent KRAS small-molecule inhibitor as the payload conjugated to an anti-epidermal growth factor receptor (EGFR) antibody; through antibody-guided delivery, the potent cell-killing payload is selectively focused on and active in tumour tissue, delivering the KRAS inhibitor directly to EGFR-expressing tumours while blocking both the EGFR and KRAS signalling pathways. Under the terms of the agreement, Hutchison MediPharma (Shanghai) Limited will lead the global Phase I development programme of HMPL-A830, expected to commence in the second half of 2026 (clinicaltrials.gov registration number: NCT07718581); the GSK subsidiary will be responsible for all subsequent clinical development and commercialisation activities outside Mainland China, Hong Kong, Macau and Taiwan.

HUTCHMED will retain all development and commercialisation rights in Mainland China, Hong Kong, Macau and Taiwan; the GSK subsidiary, GlaxoSmithKline Intellectual Property (No. 4) Limited, will pay tiered royalties based on annual net sales and holds a right of first negotiation over an earlier-stage ATTC candidate. The upfront payment will be made upon closing of the transaction, subject to customary closing conditions, including completion of any antitrust regulatory review. Mr. Zheng Zefeng, acting chief executive officer and chief financial officer of HUTCHMED, stated that this cooperation marks an important step in maximising the clinical potential of the drug, and Dr. Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D at GSK, stated that the dual KRAS-EGFR targeting mechanism of HMPL-A830 is expected to significantly improve upon current standards of care. BofA Securities is acting as the sole financial adviser to HUTCHMED.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.